Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 1, 2010, Pages 47-57

  Beck Broichsitter, Moritz ^a,b   Gauss, Julia ^a   Gessler, Tobias ^a   Seeger, Werner ^a   Kissel, Thomas ^b   Schmehl, Thomas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Biodegradable branched polyesters; Isolated lung; Nanoparticles; Nebulization; Pulmonary drug delivery; Salbutamol; Sustained release; Targeting

Indexed keywords

NANOPARTICLE; POLY(VINYL SULFONATE CO VINYL ALCOHOL); POLYGLACTIN; SALBUTAMOL; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; IN VITRO STUDY; ISOLATED LUNG; LUNG DISEASE; LUNG MODEL; LUNG VENTILATION; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; ZETA POTENTIAL;

ADMINISTRATION, INHALATION; ALBUTEROL; ANIMALS; BRONCHODILATOR AGENTS; DRUG COMPOUNDING; DRUG STABILITY; NANOPARTICLES; RABBITS; RESPIRATORY TRACT DISEASES;

EID: 76649145422     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0759     Document Type: Article

References (34)

1. Gessler T, Seeger W, and Schmehl T: Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med. 2008;21:1-12.
2. Lai YL, Mehta RC, Thacker AA, Yoo SD, McNamara PJ, and DeLuca PP: Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres. Pharm Res. 1993;10: 119-125.
3. Onischuk AA, Tolstikova TG, Sorokina IV, Zhukova NA, Baklanov AM, Karasev VV, Dultseva GG, Boldyrev VV, and Fomin VM: Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice. J Aerosol Med. 2008;21: 231-243.
4. Martin AR, Thompson RB, and Finlay WH: MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles. J Aerosol Med. 2008;21:335-341.
5. Azarmi S, Roa WH, and Loebenberg R: Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60:863-875.
6. Smola M, Vandamme T, and Sokolowski A: Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine. 2008;3:1-19.
7. Rytting E, Nguyen J, Wang X, and Kissel T: Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5:629-639.
8. Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, Seeger W, and Kissel T: Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res. 2003;20:2011-2020.
9. Dailey LA, Wittmar M, and Kissel T: The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J Control Rel. 2005;101:137-149.
10. Beck-Broichsitter M, Gauss J, Packhaeuser CB, Lahnstein K, Schmehl T, Seeger W, Kissel T, and Gessler T: Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm. 2009;367:169-178.
11. Wang X, Xie X, Cai C, Rytting E, Steele T, and Kissel T: Biodegradable branched polyesters poly(vinyl sulfonatecovinylalcohol)- graft poly(D,L-lactic-coglycolic acid) as a negatively charged polyelectrolyte platform for drug delivery: synthesis and characterization. Macromolecules 2008;41: 2791-2799.
12. Sakagami M: In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev. 2006;58:1030-1060.
13. Mobley C, and Hochhaus G: Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001;6:367-375.
14. Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernaes H, and Bengtsson UH: Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability. J Drug Target. 2003;11:61-74.
15. Ewing P, Eirefelt SJ, Andersson P, Blomgren A, Ryrfeldt A, and Gerde P: Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. J Aerosol Med. 2008;21:169-180.
16. Jung T, Breitenbach A, and Kissel T: Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J Control Rel. 2000;67:157-169.
17. Seeger W, Walmrath D, Grimminger F, Rosseau S, Schuette H, Kraemer HJ, Ermert L, and Kiss L: Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs. Methods Enzymol. 1994;233:549-584.
18. Lahnstein K, Schmehl T, Ruesch U, Rieger M, Seeger W, and Gessler T: Pulmonary absorption of aerosolized fluorescent markers in the isolated rabbit lung. Int J Pharm. 2008;351: 158-164.
19. Gibaldi M, and Perrier D: Pharmacokinetics. Marcel Dekker, Inc., New York; pp. 433-444, 1982.
20. Quintanar-Guerrero D, Allemann E, Fessi H, and Doelker E: Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24:1113-1128.
21. Barichello JM, Morishita M, Takayama K, and Nagai T: Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm. 1999;25:471-476.
22. Hyvoenen S, Peltonen L, Karjalainen M, and Hirvonen J: Effect of nanoprecipitation on the physicochemical properties of low molecular weight poly(L-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone dipropionate. Int J Pharm. 2005;295:269-281.
23. Helle A, Hirsjaervi S, Peltonen L, Hirvonen J, and Wiedmer SK: Quantitative determination of drug encapsulation in poly(lactic acid) nanoparticles by capillary electrophoresis. J Chromatogr A. 2008;1178:248-255.
24. Govender T, Stolnik S, Garnett MC, Illum L, and Davis SS: PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Rel. 1999;57:171-185.
25. Peltonen L, Aitta J, Hyvoenen S, Karjalainen M, and Hirvonen J: Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS Pharm Sci Tech. 2004;5:article 16.
26. Wittmar M, Unger F, and Kissel T: Biodegradable brushlike branched polyesters containing a charge-modified poly(vinyl alcohol) backbone as a platform for drug delivery systems: synthesis and characterization. Macromolecules 2006; 39:1417-1424.
27. Soppimath KS, Aminabhavi TM, Kulkarni AR, and Rudzinski WE: Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel. 2001;70:1-20.
28. Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, and Kissel, T: Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Rel. 2003;86: 131-144.
29. Byron PR, Roberts NSR, and Clark AR: An isolated perfused lung preparation for the study of aerosolized drug deposition and absorption. J Pharm Sci. 1986;75:168-171.
30. Tronde A, Baran G, Eirefelt S, Lennernaes H, and Bengtsson UH: Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung. J Aerosol Med. 2002;15:283-296.
31. Beck SE, Laube BL, Barberena CI, Fischer AC, Adams RJ, Chesnut K, Flotte TR, and Guggino WB: Deposition and expression of aerosolized rAAV vectors in the lungs of rhesus macaques. Mol Ther. 2002;6:546-554.
32. Clark AR: The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm. 1995;115:69-78.
33. Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, and Seeger W: Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol. 2006;215: 100-108.
34. Woolfrey SG, Taylor G, Kellaway IW, and Smith A: Pulmonary absorption of carboxyfluorescein in the rat. J Pharm Pharmacol. 1986;38:304-306.